Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor ablation · Pennsylvania | Tumor ablation · New York | |
|---|---|---|
| Surgeons, 2024 | 3 | 3 |
| Medicare fee-for-service cases | 418 | 512 |
| Growth since 2019 (Medicare FFS) | +0.9%/yr | +0.8%/yr |
| Forecast cases (Medicare FFS) | 330 in 2030 | 600 in 2030 |
| Forecast growth | −3.7%/yr to 2030 | +2.7%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.3 | 0.3 |
| Medicare Advantage share | 58% | 57% |
| Out of hospital | 0% (+0 pts since 2019) | 0% (+0 pts since 2019) |
| Cases per surgeon | 139 | 171 |
| Top 10 surgeons' share | 100% | 100% |
| Surgeons growing | 0 | 0 |
| New since the base year | 0 | 1 |
| Likely to stop billing it | 3 by 2026 | 2 by 2026 |
| Forecast miss, 1 year (procedure) | 15% | 15% |
| Company payments per surgeon | $127K | $261K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.